New Cancer Pill DOUBLES Survival!

A stethoscope next to the word 'cancer' on a yellow background — CANCER CURE BOMBSHELL

A daily pill doubled pancreatic cancer patients’ survival time over chemotherapy, offering the first real hope against this brutal killer.

Story Snapshot

Daraxonrasib achieved a median overall survival of 13.2 months versus 6.7 months with chemotherapy in metastatic pancreatic cancer.
Targets RAS mutations driving nearly all pancreatic cases, with Phase III trials advancing rapidly.
Phase I/Ib data showed 13.1-15.6 months survival, far exceeding the standard 7.4 months.
Favorable safety: only 10% severe adverse events; readout from key RASolute 302 trial due first half 2026.
Three Phase III trials target second-line, first-line, and adjuvant settings.

Daraxonrasib Targets RAS Mutations in Pancreatic Cancer

Revolution Medicines developed daraxonrasib as a multi-selective RAS(ON) inhibitor. It blocks oncogenic RAS mutations G12X, G13X, and Q61X present in nearly all pancreatic ductal adenocarcinoma cases. These mutations drive tumor growth by enabling constant RAS signaling.

Daraxonrasib suppresses this interaction with downstream effectors. Phase I/Ib trial NCT05379985 delivered positive safety and efficacy across solid tumors including PDAC. Patients saw objective response rates up to 47% and disease control over 90%.

Revolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trial https://t.co/nCo7loNB2R

— CNBC International (@CNBCi) April 13, 2026

Phase I/Ib Results Outperform Chemotherapy Benchmarks

Second-line metastatic PDAC patients on daraxonrasib monotherapy achieved median progression-free survival of 8.5 months and overall survival of 13.1 months for G12-mutant cases.

This doubled standard nab-paclitaxel/gemcitabine chemotherapy outcomes of 2.0-3.5 months PFS and 6.1-6.9 months OS. Overall survival reached 15.6 months across RAS mutations versus historical 7.4 months. Safety remained strong with no more than 10% Grade 3 treatment-related adverse events. No new signals emerged.

Phase III RASolute Trials Advance to Confirm Breakthrough

RASolute 302 enrolls about 500 second-line PDAC patients comparing daraxonrasib 300mg to investigator-choice chemotherapy. Recruitment finishes by end of 2025 with data readout in first half 2026.

RASolute 303 starts Q4 2025 testing monotherapy and GnP combination in first-line metastatic PDAC. RASolute 304 began with first patient randomized December 2025 for adjuvant resected cases. These trials validate early data across treatment lines.

Evercore ISI analyst Coy Kasimov sets success at median PFS 5-6 months and OS 10-11 months. Phase I/Ib exceeded this in small cohorts of 26 patients.

Common sense aligns with his view: even modest gains over chemo transform practice in this unmet need. Rash and GI effects warrant Phase III monitoring, but low severe event rates support viability.

📊 REVOLUTION MEDICINES' POTENTIAL BREAKTHROUGH PANCREATIC CANCER DRUG SUCCEEDS IN LATE-STAGE TRIAL

💡 Revolution Medicines' positive Phase 3 data for daraxonrasib validates RAS inhibition as a viable targeted approach in a cancer type long reliant on toxic chemo, unlocking a…

— Algofinix Inc (@algofinix) April 13, 2026

Analyst Expectations and Investment Stakes

Revolution Medicines commands $20 billion market cap on RAS inhibition promise. RASolute 302 readout tests this valuation. Positive results could spike stock; failure risks plunge.

Seven PDAC drugs now in global Phase III signal industry momentum. Daraxonrasib’s multi-selective design positions it as potential first-in-class if trials succeed.

Patient Impact and Treatment Paradigm Shift

Pancreatic cancer carries under 7% five-year survival, worst among solid tumors. Daraxonrasib could extend second-line survival from 7.4 to 13+ months, reshaping care. Success across RASolute trials establishes foundational therapy for RAS-mutant PDAC.

Patients, oncologists, and systems gain options over chemo. Precision medicine via RAS testing gains reinforcement. Limited adjuvant data exists, but RASolute 304 addresses it directly.